Kenvue Q3 2026: Revenue Beats as Kimberly-Clark Deal Nears Close

Kenvue reported Q3 2026 net sales of $3.89B, exceeding expectations. Adjusted EPS was $0.29, missing estimates due to a higher tax rate. Self Care revenue grew 5.9%, while Skin Health and Beauty remained flat. Operating income increased 12.2% YoY to $706M. The company did not provide guidance or hold an earnings call due to the pending Kimberly-Clark deal. CEO Kirk Perry stated the business transformation is progressing as planned.

Original reporting
Published Oct 30, 2026, 10:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kenvue Q3 2026: Revenue Beats as Kimberly-Clark Deal Nears Close — source image
Decision brief

The 30-second read

Med
01

Why it matters

The earnings release provides fresh data on sales growth and profitability, influencing trader expectations ahead of the merger finalization.

02

Market read

Kenvue's earnings and merger progress are material for consumer health sector investors and may affect related stocks.

03

What to watch

Higher effective tax rate and lack of guidance may weigh on near-term sentiment.

Relevance 8/10Novelty 8/10Timing: post-market release

Background

Kenvue is the consumer health spinoff of Kimberly-Clark, with the merger expected to close soon.

Market effects

Consumer health sector may see pressure as the Kimberly-Clark merger integration timeline remains uncertain.

North American consumer staples could be affected by the pending merger.

Limited to investors tracking the merger and earnings of major consumer health companies.

Counterpoint

Despite EPS miss, the revenue beat and merger synergies could support a longer-term upside.

Key entities

  • Kenvue

    Consumer health company reporting Q3 2026 results.

  • Kimberly-Clark

    Merger partner whose combination with Kenvue is nearing completion.

Related articles

$KMBMed

Kimberly-Clark Corp (KMB) (Q3 2026) Earnings Call Highlights: Kenvue Deal Closes

Kimberly-Clark (KMB) CEO Mike Hsu and CFO Nelson Urdaneta discussed Q3 2026 earnings, Kenvue integration, and 2027 outlook. Hsu highlighted Kenvue's 3% organic growth and progress in brand performance. Urdaneta cited cost-mitigating actions and easier Q4 comparisons. They addressed North America's share performance, diaper market dynamics, and synergy plans, including $1.9B in cost savings. KMB maintained fiscal 2026 guidance despite challenges.

$KMBHighAI 9/10

Kimberly-Clark Completes Kenvue Buyout Targeting $2.1 Billion in Synergies

Kimberly-Clark completed its acquisition of Kenvue on November 2, 2026, creating a personal care and consumer health group with 10 brands generating over $1 billion each in annual sales. The company targets $2.1 billion in synergies, including $1.9 billion in cost reductions within three years and $500 million in revenue gains over four years. Chief executive Mike Hsu will lead the enlarged group, which combines brands like Huggies, Kleenex, and Neutrogena.

$KMBHighAI 9/10

Clark completes $48.7bn Kenvue acquisition

Kimberly-Clark has finalized its $48.7 billion acquisition of Kenvue, adding brands like Neutrogena and Aveeno. The combined company operates in 175+ countries, with 10 global billion-dollar brands. Kimberly-Clark aims for $2.1 billion in annual financial benefits, including $1.9 billion in cost savings and $500 million in revenue synergies, offset by $300 million in reinvestment.